Beskrivning:

North Central Cancer Treatment Group N0577 Event Monitoring Form Radiation Therapy or Radiation Therapy and Temozolomide or Temozolomide Alone in Treating Patients With Newly Diagnosed Anaplastic Glioma Source Form: NCI FormBuilder: https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4C090D31-BB06-2FAA-E044-0003BA3F9857

Länk:
https://formbuilder.nci.nih.gov/FormBuilder/formDetailsAction.do?method=getFormDetails&formIdSeq=4C090D31-BB06-2FAA-E044-0003BA3F9857
Nyckelord:
  1. 2014-12-18 2014-12-18 - Martin Dugas
  2. 2015-01-08 2015-01-08 - Martin Dugas
  3. 2015-01-09 2015-01-09 - Martin Dugas
Uppladdad den:

9 januari 2015

DOI:
För en begäran logga in.
Licens :
Creative Commons BY-NC 3.0 Legacy
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Event Monitoring Form N0577

No Instruction available.

  1. StudyEvent: North Central Cancer Treatment Group N0577 Event Monitoring Form
    1. No Instruction available.
Header
Are data amended (If yes, highlight amended areas)
Were you able to obtain any information about the patient since the last report (If this is the first event monitoring form check yes, enter assessment date and complete the rest of the form.)
Vital Status
Vital Status
Primary Cause of Death
Disease Follow-up Status
Has the patient had a documented clinical assessment for this cancer? (since submission of the last event monitoring form)
Notice Of First Relapse/progression In The Event Monitoring Phase
Has the patient developed a first relapse or progression that has not been previously reported
Site of relapse/progression (s)
Method of Evaluation
Notice Of First Subsequent Treatment
Has the patient received subsequent treatment for this cancer that has not been previously reported
Notice Of New Primary
Has a new primary cancer or MDS been diagnosed that has not been previously reported? (myelodyplastic syndrome)
Description Of Primary Disease
Has the patient experienced (prior to treatment for progression or relapse or a second primary, and prior to non-protocol treatment) any severe (grade >=3) long term toxicity that has not been previously reported?
CTC AE Attribution Code

Similar models

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial